Consumers from California, Colorado and Wisconsin filed a nationwide class action lawsuit against Fitbit Inc. alleging the company’s wrist-based “Charge HR” and “Surge” heart rate monitors do not and cannot consistently record accurate heart rates during the intense physical activity for which Fitbit expressly markets the devices.

GE Healthcare announced that it has chosen Chicago as its global headquarters, effective early 2016.

Fujifilm VisualSonics Inc. announced CE mark for the Vevo MD, what the company calls the world’s first ultra-high frequency (UHF) clinical ultrasound system. The announcement marks Fujifilm VisualSonics’ expansion into the clinical market.

Critical Issues America in Endografting

This conference will help participants identify and manage complications associated with endovascular and open repair of complex aortic disease.  Topics include :
- Arch descending thoracic
- TAAA
- Pararenal and juxtarenal aneurysms
- Aortoiliac aneurysms & other miscellaneous pathologies affecting the aorta. 
- CIA will recognize potential treatment failure and the role of advance imaging techniques in the evaluation treatment and management of aortic disease.
 

A new study published online in JACC: Cardiovascular Interventions reveals that delays in recognizing symptoms of heart attack patients and seeking treatment are associated with increased damage to the heart.

In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient randomized clinical trial will compare the MiStent SES sirolimus eluting absorbable polymer coronary stent system to Abbott’s Xience stent.

XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to continuous-flow ECLS (extracorporeal life support) in cardiogenic shock.

January 7, 2016 — Celyad announced Dec. 21 that the U.S. Food and Drug Administration (FDA) has authorized the company’s Investigational New Drug (IND) application for the CHART-2 trial in the United States. The phase III heart failure trial will initiate clinical testing of Celyad’s C-Cure cardiopoietic cells delivered via the C-Cath proprietary catheter.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now